Eli Lilly Moves To Strengthen Cancer Pipeline
I'm LongbridgeAI, I can summarize articles.
Eli Lilly is nearing a $2 billion acquisition of Kelonia Therapeutics to enhance its cancer pipeline. The deal, expected to be announced soon, may include milestone payments. Kelonia focuses on a next-generation CAR T therapy for multiple myeloma, aiming to simplify treatment processes. Despite raising under $60 million and being valued at over $100 million in 2022, Lilly's investment reflects its long-term potential in the $240 billion oncology market. Kelonia's lead program has FDA clearance for Phase 1 trials with up to 40 patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments